StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Travere Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$40.46M. For fiscal 2026 it was -$62.82M. The highest annual figure on record is -$24.77M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2026Dec 31, 2025-$62.82M–
FY2025Dec 31, 2024-$323.83M–
FY2024Dec 31, 2023-$388.14M–
FY2023Dec 31, 2022-$319.81M–
FY2022Dec 31, 2021-$199.43M–
FY2021Dec 31, 2020-$176.16M–
FY2020Dec 31, 2019-$137.36M–
FY2019Dec 31, 2018-$80.04M–
FY2018Dec 31, 2017-$53.79M–
FY2017Dec 31, 2016-$58.21M–
FY2016Dec 31, 2015-$50.75M–
FY2015Dec 31, 2014-$79.81M–
FY2014Dec 31, 2013-$24.77M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$3.95M–
Q1 FY2027Mar 31, 2026-$36.92M–
Q4 FY2026Dec 31, 2025-$32.43M–
Q3 FY2026Sep 30, 2025$24.93M–
Q2 FY2026Jun 30, 2025-$12.65M–
Q1 FY2026Mar 31, 2025-$42.67M–
Q4 FY2025Dec 31, 2024-$60.74M–
Q3 FY2025Sep 30, 2024-$56.15M–
Q2 FY2025Jun 30, 2024-$67.70M–
Q1 FY2025Mar 31, 2024-$139.24M–
Q4 FY2024Dec 31, 2023-$94.23M–
Q3 FY2024Sep 30, 2023-$92.59M–
Q2 FY2024Jun 30, 2023-$103.95M–
Q1 FY2024Mar 31, 2023-$97.37M–
Q4 FY2023Dec 31, 2022-$86.70M–
Q3 FY2023Sep 30, 2022-$82.60M–
Q2 FY2023Jun 30, 2022-$78.53M–
Q1 FY2023Mar 31, 2022-$71.98M–
Q4 FY2022Dec 31, 2021-$84.85M–
Q3 FY2022Sep 30, 2021-$31.71M–
Q2 FY2022Jun 30, 2021-$35.32M–
Q1 FY2022Mar 31, 2021-$47.55M–
Q4 FY2021Dec 31, 2020-$118.55M–
Q3 FY2021Sep 30, 2020-$19.44M–
Q2 FY2021Jun 30, 2020-$23.11M–
Q1 FY2021Mar 31, 2020-$15.07M–
Q4 FY2020Dec 31, 2019-$28.17M–
Q3 FY2020Sep 30, 2019-$34.44M–
Q2 FY2020Jun 30, 2019-$36.53M–
Q1 FY2020Mar 31, 2019-$38.23M–
Q4 FY2019Dec 31, 2018-$4.99M–
Q3 FY2019Sep 30, 2018-$35.58M–
Q2 FY2019Jun 30, 2018-$21.56M–
Q1 FY2019Mar 31, 2018-$17.91M–
Q4 FY2018Dec 31, 2017-$15.18M–
Q3 FY2018Sep 30, 2017-$10.61M–
Q2 FY2018Jun 30, 2017-$13.60M–
Q1 FY2018Mar 31, 2017-$14.41M–
Q4 FY2017Dec 31, 2016-$18.22M–
Q3 FY2017Sep 30, 2016-$20.37M–

More Travere Therapeutics figures

See a number that looks wrong?